NHS National Generic Pharmaceuticals Wave 13
A Tender Notice
by ATAMIS LTD
- Source
- Contracts Finder
- Type
- Framework (Products)
- Duration
- 28 month
- Value
- £470M
- Sector
- HEALTH
- Published
- 19 Jan 2022
- Delivery
- 01 Feb 2022 to 31 May 2024
- Deadline
- 26 Jul 2021 13:00
Concepts
Location
1 buyer
- Atamis Runcorn
Description
Invitation to offer for NHS National Generic Pharmaceuticals Wave 13 Offer reference number: CM/PHG/17/5532 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Transition (Everolimus) CESW: 1 March 2022 - 30 September 2023 (19 months) LSNE: 1 March 2022 - 31 January 2023 (11 months) NWLN: 1 March 2022 - 31 January 2023 (11 months) Oral Products plus non-parenterals All Regions: 1 March 2022 - 31 May 2024 (27 months) Hospital Only Products CESW: 1 February 2022 - 30 September 2023 (20 months) LSNE: 1 February 2022 - 31 May 2024 (28 months) NWLN: 1 February 2022 - 31 January 2023 (12 months)
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Contract is suitable for SMEs.
Reference
- CF-0572600D0O000000rwimUAA1
- CF 2b45447f-b07a-4024-8b3a-2a2f2fd86749